GenVec Reports Fourth Quarter And 2014 Year-End Financial Results

GAITHERSBURG, Md., March 24, 2015 -- GenVec, Inc. (GNVC) today reported financial results for the fourth quarter and year ended December 31, 2014. For the year ended December 31, 2014, the company reported a net loss of $2.5 million, or $0.16 per share, compared with a net loss of $10.0 million, or $0.77 per share, for the year ended December 31, 2013. The company ended the year with $14.7 million in cash, cash equivalents, and short-term investments. 

"The significant progress we made in 2014 has set the stage for an exciting new chapter in our evolution. Most notably, a Phase 1/2 clinical trial commenced for CGF166, GenVec's lead product candidate which is partnered with Novartis, in patients with severe to profound hearing loss," said Douglas J. Swirsky, president and CEO of GenVec.

Published: 24 March 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: GenVec Inc ( GNVC )

Coherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results

Strong Clinical Performance and Financial Milestones Achieved

REDWOOD CITY, Calif., March 23, 2015 -- Coherus BioSciences, Inc. (CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the quarter and fiscal year ended December 31, 2014.

2014 Highlights:

  • CHS-1701 (pegfilgrastim (Neulasta(R)) biosimilar): completed Phase 1 351(a) (novel biologic) study and transitioning to a 351(k) (biosimilar) approval pathway. In March 2015, the Company initiated a pivotal study, which, if positive, could support the filing of a 351(k) biologics license application (BLA) in the fourth quarter of 2015 or first quarter of 2016. An additional immunogenicity study is planned in healthy volunteers pursuant to this BLA and is projected to be concluded in 2015 to support submission of the BLA.
    Published: 24 March 2015
    Written by Editor
    Nasdaq   Financial Results   Up on News  
    Read more: Coherus BioSciences Inc ( CHRS )

Takeda Licenses Rights to Use ImmunoGen, Inc.’s Novel Antibody-Drug Conjugate Technology

CAMBRIDGE & WALTHAM, Mass.-- Takeda Pharmaceutical Company Limited (TSE:4502) and ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its state-of-the-art antibody-drug conjugate (ADC) technology, today announced that Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology – including ImmunoGen’s new DNA-acting IGN payload agents – to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets. The agreement also provides Takeda with the option to take a license for a third target for an additional upfront fee.

ImmunoGen will receive $20 million upfront and – for each target – is eligible to receive milestone payments potentially totaling up to $210 million plus royalties on the commercial net sales of any resulting ADC products. Takeda is responsible for the development, manufacturing and marketing of any ADC products resulting from this agreement.

Published: 23 March 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: ImmunoGen Inc ( IMGN )

Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease

  • All Doses of PRX002 Found to be Safe and Well Tolerated, Meeting Primary Objective of Phase 1 Single Ascending Dose Study
  • Results of Study Demonstrate Rapid and Dose-Dependent Reduction of Free Serum Alpha-Synuclein, Potential Disease-Causing Protein in Parkinson`s Disease

DUBLIN, Ireland, March 19, 2015  -- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced positive results from a Phase 1 single ascending dose study of PRX002, a monoclonal antibody for the potential treatment of Parkinson`s disease and other related synucleinopathies. PRX002 is the focus of a worldwide collaboration between Prothena and Roche.

Published: 20 March 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Prothena Corporation plc (PRTA)

Juno Therapeutics Reports Fourth Quarter and 2014 Financial Results

Conference call to be held on Wednesday, March 18, 2015 at 5:00 p.m. Eastern Time

  • Positive momentum and progress on clinical trials continues
  • Strong year-end cash position of $474.1 million
  • 2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and ongoing litigation

SEATTLE, March 18, 2015 -- Juno Therapeutics, Inc. (JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2014.

Published: 19 March 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Juno Therapeutics Inc ( JUNO )
  1. Amicus Therapeutics ( FOLD )
  2. Coronado Biosciences Inc ( CNDO )
  3. Can-Fite BioPharma Ltd ( CANF )
  4. Retrophin Inc ( RTRX )
  5. Novogen Limited ( NVGN )